Overview

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

Status:
Completed
Trial end date:
2020-08-10
Target enrollment:
Participant gender:
Summary
This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.
Phase:
Phase 2
Details
Lead Sponsor:
Resolve Therapeutics